Today: 29 April 2026
Browse Category

NASDAQ:ADPT 19 August 2025 - 6 February 2026

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer shares closed Monday at $26.43, up 2.24%, then slipped to $26.34 after hours. Investors are awaiting Tuesday’s analyst call, where management is set to outline 2026 guidance. The company announced a new autoimmune research deal with Adaptive Biotechnologies, worth up to $890 million in milestones. Trading volume was about 60 million shares, below average.
16 December 2025
···
Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

The S&P 500 closed at 6,870.40, up 0.19% Friday, while Bitcoin fell 3% to just under $89,300. Parsons plunged 21% after losing a key FAA contract; other steep U.S. decliners included Adaptive Biotechnologies, SentinelOne, and several Brazilian financials. Brazil’s Bovespa index dropped 4% after Jair Bolsonaro endorsed his son for president, sending the real down 3%.
6 December 2025
··········
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····

Stock Market Today

  • Microsoft (MSFT) Valuation Overview After 30-Day 20% Share Rally
    April 28, 2026, 9:52 PM EDT. Microsoft's stock has rebounded 20.3% over the past 30 days, reversing earlier declines that put the year-to-date return at -9.2%. Despite this bounce, the one-year return stands near 9.8%, while its longer-term gains are more robust-43.9% over three years and 80.5% over five years. Investors are weighing these moves against valuation metrics like the Price-to-Earnings (P/E) ratio and Discounted Cash Flow (DCF) models. The DCF approach projects future free cash flows rising to an estimated US$174.3 billion by 2030, setting an intrinsic value benchmark. This mix of recent share price gains and fundamental models informs portfolio decisions. Tools like Simply Wall St's valuation scorecards help compare Microsoft to peers, offering a multidimensional view beyond single ratios.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop